Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In this randomized trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo.
Saved in:
| Published in: | The New England journal of medicine Vol. 392; no. 16; pp. 1569 - 1581 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
24.04.2025
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!